Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study.
暂无分享,去创建一个
J. Metcalf | R. Davey | M. Baseler | S. Vogel | J. Kovacs | M. Polis | R. Walker | J. Falloon | H. Masur | H. Lane | R. Stevens | N. Salzman | R T Davey | N P Salzman | J A Kovacs | M Baseler | R J Dewar | S Vogel | J Falloon | M A Polis | R E Walker | R Stevens | R. Walker | R. Dewar | Robin Dewar
[1] M. Urdea,et al. Direct and quantitative detection of HIV‐1 RNA in human plasma with a branched DNA signal amplification assay , 1993, AIDS.
[2] A. Fauci,et al. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. , 1983, The Journal of clinical investigation.
[3] M A Fischl,et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. , 1987, The New England journal of medicine.
[4] H. Mitsuya,et al. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. , 1989, Science.
[5] J. Kovacs,et al. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. , 1990, Annals of internal medicine.
[6] D. Stites,et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. , 1986, Clinical immunology and immunopathology.
[7] S. J. Clark,et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.
[8] R. Dewar,et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. , 1994, The Journal of infectious diseases.
[9] S. Steinberg,et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. , 1994, The Journal of infectious diseases.
[10] D. Richman,et al. Combination Therapy with Zidovudine and Dideoxycytidine in Patients with Advanced Human Immunodeficiency Virus Infection , 1992, Annals of Internal Medicine.
[11] S. Rosenberg,et al. Clinical effects and toxicity of interleukin‐2 in patients with cancer , 1986, Cancer.
[12] R. Davey,et al. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection. , 1994, The Journal of infectious diseases.
[13] M. Caligiuri,et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. , 1993, The Journal of clinical investigation.
[14] J V Giorgi,et al. Application of flow cytometry to the study of HIV infection. , 1990, AIDS.
[15] P. Mazza,et al. Recombinant interleukin‐2 (rIL‐2) in acquired immune deficiency syndrome (AIDS): Preliminary report in patients with lymphoma associated with HIV infection , 1992, European journal of haematology.
[16] M. Clerici,et al. T helper cell immune dysfunction in asymptomatic, HIV-1-seropositive individuals: the role of TH1-TH2 cross-regulation. , 1992, Chemical immunology.
[17] A. Capron,et al. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals , 1992, The Journal of experimental medicine.
[18] R. Detels,et al. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. , 1989, Clinical immunology and immunopathology.
[19] S. Banks,et al. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma. A phase II randomized, placebo-controlled trial. , 1989, Annals of internal medicine.
[20] D. Venzon,et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. , 1993, The Journal of clinical investigation.
[21] G. Kaplan,et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. , 1993, The Journal of infectious diseases.
[22] M. Baseler,et al. ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA , 1988, The Lancet.
[23] Kendall A. Smith,et al. Interleukin-2: inception, impact, and implications. , 1988, Science.
[24] D. Longo,et al. Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. , 1985, The American journal of medicine.
[25] E. Gelmann,et al. Use of interleukin-2 in patients with acquired immunodeficiency syndrome. , 1984, Journal of biological response modifiers.
[26] T. Merigan,et al. Safety and Effects of Interleukin‐2 Plus Zidovudine in Asymptomatic Individuals Infected with Human Immunodeficiency Virus , 1991, Journal of acquired immune deficiency syndromes.
[27] M. Kimoto,et al. Antigen-reactive T cell clones. I. Transcomplementing hybrid I-A-region gene products function effectively in antigen presentation , 1980, The Journal of experimental medicine.
[28] J. Nielsen,et al. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group. , 1990, The New England journal of medicine.
[29] R. Schooley,et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. , 1989, Annals of internal medicine.
[30] K. Squires,et al. Interleukin-2 treatment, interferon-γ induction, and AIDS monocyte activation , 1992 .
[31] P. Dietrich,et al. Influence of interleukin‐2 administration on the expression of T‐cell receptor V gene segments in patients with renal‐cell carcinoma , 1993, International journal of cancer.
[32] H. Lane,et al. Participation of tyrosine phosphorylation in the cytopathic effect of human immunodeficiency virus-1. , 1992, Science.
[33] A. Capron,et al. CD3‐mediated apoptosis of human medullary thymocytes and activated peripheral T cells: Respective roles of interleukin‐1, interleukin‐2, interferon‐γ and accessory cells , 1993, European journal of immunology.
[34] R. Puri,et al. Interleukin-2 toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] C. Trépo,et al. RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DITIOCARB SODIUM ('IMUTHIOL') IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION , 1988, The Lancet.
[36] R. Dewar,et al. Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[37] G. Kaplan,et al. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection , 1993, The Journal of experimental medicine.
[38] P. Volberding,et al. Therapy of acquired immune deficiency syndrome with recombinant interleukin-2. , 1987, AIDS research and human retroviruses.
[39] J. Fahey,et al. Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection. , 1993, Journal of immunology.
[40] J. Metcalf,et al. Interferon-α in patients with asymptomatic human immunodeficiency virus (HIV) infection. , 1990 .